149 related articles for article (PubMed ID: 25398843)
1. The evolving role of molecular markers in the diagnosis and management of diffuse glioma.
Huse JT; Aldape KD
Clin Cancer Res; 2014 Nov; 20(22):5601-11. PubMed ID: 25398843
[TBL] [Abstract][Full Text] [Related]
2. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
3. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
5. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
Riemenschneider MJ; Reifenberger G
Curr Opin Neurol; 2009 Dec; 22(6):619-24. PubMed ID: 19741528
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
9. Pathological classification of brain tumors.
Pollo B
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
11. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
[TBL] [Abstract][Full Text] [Related]
12. Pediatric high grade gliomas: A comprehensive histopathological, immunohistochemical and molecular integrated approach in routine practice.
Das S; Ahlawat S; Panda AK; Sarangi J; Jain P; Gupta RK; Vaishya S; Patir R
Pathol Res Pract; 2024 Jun; 258():155347. PubMed ID: 38763090
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
[TBL] [Abstract][Full Text] [Related]
14. The molecular landscape of diffuse glioma and prospects for biomarker development.
Huse JT; Aldape KD
Expert Opin Med Diagn; 2013 Nov; 7(6):573-87. PubMed ID: 24161073
[TBL] [Abstract][Full Text] [Related]
15. Molecular neuro-oncology in clinical practice: a new horizon.
Weller M; Pfister SM; Wick W; Hegi ME; Reifenberger G; Stupp R
Lancet Oncol; 2013 Aug; 14(9):e370-9. PubMed ID: 23896276
[TBL] [Abstract][Full Text] [Related]
16. Molecular subclassification of diffuse gliomas: seeing order in the chaos.
Huse JT; Phillips HS; Brennan CW
Glia; 2011 Aug; 59(8):1190-9. PubMed ID: 21446051
[TBL] [Abstract][Full Text] [Related]
17. Genetic markers in adult high-grade gliomas.
Pekmezci M; Perry A
Semin Radiat Oncol; 2014 Oct; 24(4):235-9. PubMed ID: 25219807
[TBL] [Abstract][Full Text] [Related]
18. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
19. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
20. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
